Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis

Expert Opinion on Investigational Drugs

Volumn 22, Issue 12, 2013, Pages 1603-1611

  Gowin, Krisstina ^a   Mesa, Ruben ^a  

^a MAYO CLINIC   (United States)

Author keywords

Myelofibrosis; Myeloid neoplasm; Myeloproliferative neoplasms

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 5 AZA 2' DEOXYCYTIDINE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ANDROGEN; AZACITIDINE; BMS 911543; BORTEZOMIB; BUSULFAN; DANAZOL; ERYTHROPOIETIN; EVEROLIMUS; FEDRATINIB; GANDOTINIB; GIVINOSTAT; HYDROXYUREA; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; MELPHALAN; MOMELOTINIB; NS 018; PACRITINIB; PEGINTERFERON ALPHA2A; POMALIDOMIDE; PRACINOSTAT; PREDNISONE; RUXOLITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ABDOMINAL PAIN; ANEMIA; CYTOPENIA; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; ECCHYMOSIS; FATIGUE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERLIPASEMIA; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; LEUKOCYTOSIS; LEUKOPENIA; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE NEOPLASM ASSOCIATED MYELOFIBROSIS; REVIEW; SIDE EFFECT; SPLENECTOMY; SPLENOMEGALY; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ANIMALS; HUMANS; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME;

EID: 84887736491     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.832199     Document Type: Review

References (74)

1. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007;31(6):737-40
2. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012;30(33):4098-103
3. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: A prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009;114(26):5264-70
4. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010;89(12):1233-7
5. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434(7037):1144-8. JAK2V617F identification.
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352(17):1779-90
7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer cell 2005;7(4):387-97
8. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003;3(11):900-11
9. Abdel-Wahab O, Tefferi A, Levine RL. Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematology 2012;26(5):1053-64
10. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360(22):2289-301
11. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010;116(6):988-92
12. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270
13. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012;12(9):599-612
14. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24(6):1128-38
15. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011;118(7):1723-35
16. Zhang SJ, Abdel-Wahab O. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms. Curr Hematol Malignancy Rep 2012;7(1):34-42
17. Jamieson CH, Barroga CF, Vainchenker WP. Miscreant myeloproliferative disorder stem cells. Leukemia 2008;22(11):2011-19
18. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23(33):8520-30
19. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011;29(10):1356-63
20. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J (Sudbury Mass) 2007;13(6):377-83
21. Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011;29(17):2410-15
22. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003;74(1):26-31
23. Cervantes F, Pereira A. Advances in the understanding and management of primary myelofibrosis. Curr Opin Oncol 2011;23(6):665-71
24. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 2009;113(22):5394-400
25. Singh PP, Timucin T, Nagorney DM, Tefferi A. Splenectomy for Massive Splenomegaly Associated with Myelofibrosis: Outcomes From 63 Patients At Mayo Clinic. ASH Annu Meet Abstr 2012;120(21):2848
26. Pardanani A, Brown P, Neben-Wittich M, et al. Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy. Am J Hematol 2010;85(9):715-16
27. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009;83(2):154-5
28. Tefferi A, Silverstein MN. Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1994;86(4):893
29. Tsiara SN, Chaidos A, Bourantas LK, et al. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Acta Haematol 2007;117(3):156-61
30. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807. COMFORT I study.
31. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl Med 2012;366(9):787-98. COMFORT II study.
32. Cervantes F, Kiladjian J-J, Niederwieser D, et al. Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF). ASH Annu Meet Abstr 2012;120(21):801
33. Hans-Michael Kvasnicka JT, Carlos E. Bueso-Ramos. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. J Clin Oncol 2013;31(Suppl):abstract 7030
34. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013;88(4):318-27
35. Li L, Bailey E, Greenblatt S, et al. Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice. Blood 2011;118(18):4935-45
36. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29(7):789-96
37. Pardanani A, Gotlib J, Jamieson C, et al. SAR302503: Interim safety, efficacy, and long term impact of JAK2 V617F allele burden in a phase I/II study in patients with myelofibrosis. Blood 2011;118(Suppl 1):abstract 3838
38. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110(12):4030-6
39. Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006;107(5):2098-100
40. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114(8):1477-83
41. Talpaz M, Jamieson C, Gabrail NY, et al. A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF. ASH Annu Meet Abstr 2012;120(21):2837
42. Animesh Dev Pardanani CHMJ, Nashat Y. Gabrail, et al. Updated results from a randomized phase II dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with myelofibrosis (MF). J Clin Oncol 2013;31(Suppl): abstract 7109. ASCO update of SAR302503.
43. Talpaz M, Jamieson CHM, Gabrail NY, et al. Modulation of plasma cytokines and its association with clinical response to treatment with the JAK2-selective inhibitor SAR302503 in myelofibrosis (MF). J Clin Oncol 2013;31(Suppl):abstract 7110
44. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115(25):5232-40
45. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27(6):1322-7
46. Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011;25(11):1751-9
47. Komrokji RS WM, Seymour JF, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral Jak2 inhibitor in patients with primary, post-polycythemia vera, and post essential thrombocythemia myelofibrosis. Blood 2011;2011(Suppl1):abstract 282
48. Deeg HJ OO, Scott BL, et al. Phase II study of SB1518, an orally available novel Jak2 inhibitor, in patients with myelofibrosis. J Clin Oncol 2011;29(Suppl):abstract 6515. ASCO update of SB1518.
49. Verstovsek S, Al-Fayoumi S, Komrokji R, et al. Safety overview of phase i-ii studies of pacritinib, a non-myelosuppressive jak2/flt3 inhibitor, in patients with hematological malignancies. EHA 2013 (EHA18ABSSUB-3809)
50. Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: Cytogenetic and JAK2V617F molecular remissions. Leukemia 2007;21(8):1827-8
51. Barosi G, Elliott M, Canepa L, et al. Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002;43(12):2301-7
52. Schlenk RF, Reiter A, Gattermann N, et al. Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01-09 Study (ClinicalTrials.gov Identifier: NCT00949364). ASH Annu Meet Abstr 2012;120(21):2840
53. Begna KH PA, Mesa R, Litzow MR, et al. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012;87(1):66-8. POM Phase II trial.
54. Shastri A, Cortes JE, Jabbour EJ, et al. A Phase II Study of Low-Dose Pomalidomide (0.5mg/day) and Prednisone Combination Therapy in Patients with Myelofibrosis and Significant Anemia. ASH Annu Meet Abstr 2012;120(21):1728
55. Grimwade LF, Happerfield L, Tristram C, et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol 2009;147(4):495-506
56. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011;118(8):2069-76
57. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004;32(2):179-87
58. Choong ML, Pecquet C, Tai SJ, et al. Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms. ASH Annu Meet Abstr 2012;120(21):180
59. Vannucchi AM, Bartalucci N, Bogani C, et al. Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease. ASH Annu Meet Abstr 2012;120(21):708
60. Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009;461(7265):819-22
61. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150(4):446-55
62. Quintas-Cardama A, Kantarjian H, Estrov Z, et al. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leukemia Res 2012;36(9):1124-7
63. Andersen CL, Mortensen N, Vestergaard H, et al. A Phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera myelofibrosis (PPV-MF). EHA 2013; EHA18ABSSUB-4340
64. Wagner-Ballon O, Pisani DF, Gastinne T, et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood 2007;110(1):345-53
65. Mesa RA, Verstovsek S, Rivera C, et al. Bortezomib therapy in myelofibrosis: A phase II clinical trial. Leukemia 2008;22(8):1636-8
66. Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 2001;97(6):1896
67. Gowin K, Thapaliya P, Samuelson J, et al. Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012;97(10):1570-3
68. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011;117(18):4706-15
69. Ianotto JC, Kiladjian JJ, Demory JL, et al. PEG-IFN-alpha-2a therapy in patients with myelofibrosis: A study of the French Groupe dEtudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol 2009;146(2):223-5
70. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: A preliminary report. Blood 2011;117(24):6669-72
71. Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 2013; [Epub ahead of print]
72. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112(8):3065-72
73. Nguyen HM, Kiladjian JJ. Is there a role for the use of IFN-alpha in primary myelofibrosis Hematology (Am Soc Hematol Educ Program) 2012;2012:567-70
74. Levine RL, Koppikar P, Marubayashi S, et al. Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo. ASH Annu Meet Abstr 2012;120(21):805